117 related articles for article (PubMed ID: 21176979)
1. Dobutamine-induced changes of left atrial two-dimensional deformation predict clinical and neurohumoral improvement after levosimendan treatment in patients with acutely decompensated chronic heart failure.
Paraskevaidis IA; Ikonomidis I; Parissis J; Papadopoulos C; Stassinos V; Bistola V; Anastasiou-Nana M
Int J Cardiol; 2012 May; 157(1):31-7. PubMed ID: 21176979
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure.
Paraskevaidis IA; Bistola V; Ikonomidis I; Parissis JT; Papadopoulos C; Filippatos G; Kremastinos DT
Am J Cardiol; 2008 Nov; 102(9):1225-9. PubMed ID: 18940297
[TBL] [Abstract][Full Text] [Related]
3. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure.
Duman D; Palit F; Simsek E; Bilgehan K; Sacide A
Can J Cardiol; 2009 Oct; 25(10):e353-6. PubMed ID: 19812809
[TBL] [Abstract][Full Text] [Related]
4. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
[TBL] [Abstract][Full Text] [Related]
5. Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.
Farmakis D; Parissis JT; Bistola V; Paraskevaidis IA; Iliodromitis EK; Filippatos G; Kremastinos DT
Int J Cardiol; 2010 Feb; 139(1):75-9. PubMed ID: 18973957
[TBL] [Abstract][Full Text] [Related]
6. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
7. Effects of levosimendan on left atrial functions in patients with ischemic heart failure.
Duygu H; Nalbantgil S; Ozerkan F; Zoghi M; Akilli A; Erturk U; Akin M; Nazli C; Ergene O
Clin Cardiol; 2008 Dec; 31(12):607-13. PubMed ID: 19072879
[TBL] [Abstract][Full Text] [Related]
8. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
[TBL] [Abstract][Full Text] [Related]
9. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
Işık S; Cetin M; Ciçekçioğlu H; Uçar O; Çetin ZG; Ozuğuz U; Bakır F; Berker D; Güler S
Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501
[TBL] [Abstract][Full Text] [Related]
10. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
[TBL] [Abstract][Full Text] [Related]
11. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.
Cetin M; Uçar O; Cicekçioğlu H; Güven Cetin Z; Sahin M; Vasfi Ulusoy F; Aydoğdu S
Acta Cardiol; 2012 Jun; 67(3):317-23. PubMed ID: 22870740
[TBL] [Abstract][Full Text] [Related]
13. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
[TBL] [Abstract][Full Text] [Related]
14. Multidimensional contractile reserve predicts adverse outcome in patients with severe systolic heart failure: a 4-year follow-up study.
Paraskevaidis IA; Ikonomidis I; Simitsis P; Parissis J; Stasinos V; Makavos G; Lekakis J
Eur J Heart Fail; 2017 Jul; 19(7):846-861. PubMed ID: 28220640
[TBL] [Abstract][Full Text] [Related]
15. Carvedilol improves left atrial and left ventricular function and reserve in dilated cardiomyopathy after 1 year of treatment.
Paraskevaidis I; Farmakis D; Parissis JT; Dodouras T; Filippatos G; Tsiapras D; Kremastinos DT
J Card Fail; 2007 Mar; 13(2):108-13. PubMed ID: 17395050
[TBL] [Abstract][Full Text] [Related]
16. NT-proBNP response to dobutamine stress echocardiography predicts left ventricular contractile reserve in dilated cardiomyopathy.
Parthenakis FI; Patrianakos AP; Haritakis CN; Zacharis EA; Nyktari EG; Vardas PE
Eur J Heart Fail; 2008 May; 10(5):475-81. PubMed ID: 18396456
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan allows detection of contractile reserve in patients with chronic ischaemic left ventricular dysfunction and non-diagnostic dobutamine echocardiography.
Cianfrocca C; Pelliccia F; Auriti A; Guido V; Pasceri V; Li X; Richichi G; Mercuro G; Santini M
Eur J Heart Fail; 2007 Sep; 9(9):897-900. PubMed ID: 17572145
[TBL] [Abstract][Full Text] [Related]
18. Effects of levosimendan/furosemide infusion on plasma brain natriuretic peptide, echocardiographic parameters and cardiac output in end-stage heart failure patients.
Feola M; Lombardo E; Taglieri C; Vallauri P; Piccolo S; Valle R
Med Sci Monit; 2011 Feb; 17(3):PI7-13. PubMed ID: 21358614
[TBL] [Abstract][Full Text] [Related]
19. Effects of levosimendan on quality of life and emotional stress in advanced heart failure patients.
Parissis JT; Papadopoulos C; Nikolaou M; Bistola V; Farmakis D; Paraskevaidis I; Filippatos G; Kremastinos D
Cardiovasc Drugs Ther; 2007 Aug; 21(4):263-8. PubMed ID: 17610056
[TBL] [Abstract][Full Text] [Related]
20. Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure.
Lunghetti S; Palmerini E; Urselli R; Maffei S; Guarino E; Focardi M; Mondillo S; Favilli R
Cardiol J; 2011; 18(5):532-7. PubMed ID: 21947989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
